Nivo/Ipi Combo Now'Standard of Care' in Mesothelioma Nivo/Ipi Combo Now'Standard of Care' in Mesothelioma
Patients with malignant pleural mesothelioma have a marked and sustained overall survival benefit with nivolumab and ipilimumab vs chemotherapy, even if they discontinue treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Improved Survival in Patients With NSCLC and Brain Metastases Improved Survival in Patients With NSCLC and Brain Metastases
About a third of the patients with NSCLC and brain metastases treated with atezolizumab in combination with chemotherapy had overall survival improved to 2 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Exercise Habit Prior to Breast Cancer Chemo May Aid Cognition
Adherence to physical activity guidelines throughout chemotherapy was associated with better self - reported cognition (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 8, 2021 Category: Cancer & Oncology Tags: Gynecology, Neurology, Oncology, Pharmacy, Journal, Source Type: news

Exercise Habit Prior to Breast Cancer Chemo May Aid Cognition
WEDNESDAY, Sept. 8, 2021 -- Doing more physical activity before undergoing chemotherapy and adhering to national physical activity guidelines during chemotherapy are associated with better cognition over time among patients with breast cancer,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 8, 2021 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mesothelioma Treatment Program Expanding in Central Florida
When he first joined AdventHealth Orlando in 2019, thoracic surgeon Dr. Marcelo DaSilva wondered just how successful he could be in creating a mesothelioma specialty center in Central Florida. Now he knows. DaSilva was initially hoping to create a program that would allow Florida mesothelioma patients to stay closer to home – instead of traveling across the country – and still get the best possible treatment for this rare, tough-to-treat malignancy. But he’s already done considerably more. His vision has grown, and so has his program. More patients will benefit greatly. DaSilva recently expand...
Source: Asbestos and Mesothelioma News - September 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
510(k) Device May Improve Targeted Delivery of Chemotherapy LOS ALTOS, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announc... Devices, Drug Delivery, Oncology, FDA RenovoRx, RenovoCath Delivery System, RenovoGem, RenovoTAMP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2021 Category: Pharmaceuticals Source Type: news

Chemotherapy Induced Immune Microenvironment Changes in TNBC Chemotherapy Induced Immune Microenvironment Changes in TNBC
A better understanding of the impacts of neoadjuvant chemotherapy on the immune microenvironment could have important prognostic implications in triple-negative breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease
We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

What's the best way to halt my hair loss? DR MARTIN SCURR answers your health questions
DR MARTIN SCURR: Many drugs can trigger hair loss, including statins, immunosuppressants, antidepressants and, of course, those used in chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2021 Category: Consumer Health News Source Type: news

Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study. Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma. Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients. “Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particu...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Therapies Have Transformed Acute Lymphoblastic Leukemia Care New Therapies Have Transformed Acute Lymphoblastic Leukemia Care
Novel, chemotherapy-free regimens are poised to become standard of care in Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 27, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTN...
Source: Roche Media News - August 27, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq ® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTN...
Source: Roche Investor Update - August 27, 2021 Category: Pharmaceuticals Source Type: news

Mesothelioma Olaparib Clinical Trial Targets Genetic Mutation
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposu...
Source: Asbestos and Mesothelioma News - August 24, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

CT radiomic features predict gastric cancer chemotherapy response
A CT-based radiomics model helped clinicians predict response to neoadjuvan...Read more on AuntMinnie.comRelated Reading: AI predicts metastasis in gastric cancer patients AI may predict lymph node metastasis in gastric cancer AIUM: Double dose of US contrast helps find gastric lesions Surgery plus RT works best for metastatic gastric cancer ASCO GI: CT unnecessary for staging early gastric cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 19, 2021 Category: Radiology Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early - Onset CRC Biologically Similar to Average - Onset CRC
No significant differences seen at gene or pathway level according to age; chemotherapy response, survival equivalent by age groups (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 18, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Pathology, Radiology, Surgery, Journal, Source Type: news

Scan that can predict how well chemotherapy will work
The scan, which involves waving a probe resembling a shower head over the tumour site, can detect tiny changes that indicate whether it is responding to chemo drugs after one round of treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - August 17, 2021 Category: Consumer Health News Source Type: news

Wake Forest School of Medicine research looks at the relationship between diet and cancer
A modified ketogenic diet may be worth exploring for people with brain tumors, according to a new study published in the July 7 online issue of Neurology, the medical journal of the American Academy of Neurology. The diet is high in fat and low in carbohydrates. The small study found that the diet was safe and feasible for people with brain tumors called astrocytomas. All of the people had completed radiation treatment and chemotherapy. The diet led to changes in the metabolism in the body and the… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 15, 2021 Category: Health Management Authors: Wake Forest Baptist Health Source Type: news

Wake Forest School of Medicine research looks at the relationship between diet and cancer
A modified ketogenic diet may be worth exploring for people with brain tumors, according to a new study published in the July 7 online issue of Neurology, the medical journal of the American Academy of Neurology. The diet is high in fat and low in carbohydrates. The small study found that the diet was safe and feasible for people with brain tumors called astrocytomas. All of the people had completed radiation treatment and chemotherapy. The diet led to changes in the metabolism in the body and the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 15, 2021 Category: Biotechnology Authors: Wake Forest Baptist Health Source Type: news

Chemotherapy-immunotherapy combination may work in lung cancer, study finds
A combination of two cancer treatments to target immune cells involved with the formation of lung tumors could provide an effective treatment for lung cancer, according to a study published Wednesday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 11, 2021 Category: Consumer Health News Source Type: news

Hysterectomy, Chemo Fraud Allegations Settled by Hospitals, DOJ Hysterectomy, Chemo Fraud Allegations Settled by Hospitals, DOJ
A gynecologic oncologist allegedly performed unnecessary radical hysterectomies and gave unneeded chemotherapy to patients at four hospitals in Michigan.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

COVID-19 Booster Shots Are Still Controversial —Even for the Immunocompromised People Who Likely Need Them the Most
Chris Neblett, 44, was among the first people in the U.S. to get vaccinated against COVID-19. His job with the U.S. State Department allowed him to get his initial dose of Pfizer-BioNTech’s vaccine in late December 2020. By January 2021, he was fully vaccinated. But that didn’t mean he was fully protected. Neblett, who received a kidney transplant in 2018 and still takes immune-system-suppressing drugs to prevent his body from rejecting the organ, found out through his participation in a Johns Hopkins study of vaccination among transplant patients that he didn’t produce any disease-fighting antibodies, ev...
Source: TIME: Health - August 11, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news

Chemotherapy-induced peripheral neuropathy increases nontraumatic fracture risk in breast cancer survivors - McNeish BL, Richardson JK, Bell SG, Whitney DG.
Chemotherapy is a common treatment for breast cancer (BrCa) and can cause chemotherapy-induced peripheral neuropathy (CIPN). CIPN contributes to falls, and is thus a potential risk factor for nontraumatic fractures (NTFx); yet, the effect of CIPN on NTFx r... (Source: SafetyLit)
Source: SafetyLit - August 11, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Meet the All-Civilian Crew of Inspiration4, From a St. Jude ’s Physician Assistant to a Lockheed Martin Engineer
Astronauts are accustomed to celebrity status, and Jared Isaacman, 41, is learning that truth first-hand. Isaacman is the billionaire CEO of Shift4 Payments, an online payment company, who bought all four seats aboard a SpaceX Crew Dragon spacecraft and, come September, will command Inspiration4, the first orbital space mission crewed entirely by non-professional astronauts. But if Isaacman’s name is becoming increasingly well-known in space circles, those of the other crew members are less so. Here’s a look at who they are, how they were selected to make their improbable journey, and what they hope to accompli...
Source: TIME: Science - August 10, 2021 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Space Special Project Source Type: news

Why giving blood could help save cancer patients
Melody, 44, had suspected that her son Andrew Berthoud had chickenpox. It was acute lymphoblastic leukaemia and he needed chemotherapy and 22 blood transfusions. (Source: the Mail online | Health)
Source: the Mail online | Health - August 9, 2021 Category: Consumer Health News Source Type: news

Large PICC Size May Up Risk for Thrombosis in Cancer Patients
MONDAY, Aug. 9, 2021 -- Cancer patients receiving chemotherapy intravenously have more than double the risk for developing a blood clot if the catheter occupies more than 45 percent of the vein, according to a study recently published online in BMJ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 9, 2021 Category: Pharmaceuticals Source Type: news

Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when combined with aggressive surgery for patients with malignant pleural mesothelioma. Although the U.S. National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the adjuvant radiation – as do many specialists – the Duke research team has challenged the conventional treatment with this report. “The receipt of adjuvant hemithoracic radiation was not associated with improved survival when compared to no radiation,&rdq...
Source: Asbestos and Mesothelioma News - August 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study: Treatment at Academic Facilities Extends Mesothelioma Survival
More than half of patients with peritoneal mesothelioma cancer in the United States are being treated at community hospitals, sacrificing the chance to extend survival at an academic/research facility. Too many die sooner than they should. A medical research team at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, has shown that median survival is more than twice as long for patients treated at an academic facility compared to those at a community hospital. “Malignant peritoneal mesothelioma patients may be better served at experienced, academic centers,” the authors ...
Source: Asbestos and Mesothelioma News - August 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Trial to test if cannabis-based mouth spray can treat brain tumours
First such study in the world aims to find out if Sativex combined with chemotherapy can help treat glioblastomaCancer charities and the NHS are preparing to investigate whether a cannabis-based mouth spray can treat brain tumours and help patients to live longer.Doctors will give patients across the UK with a recurrent brain tumour called a glioblastoma the drug, which is known as Sativex, alongside a chemotherapy medication – temozolomide – in a clinical trial in an attempt to kill off cancerous cells.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2021 Category: Science Authors: Denis Campbell Health policy editor Tags: Cancer Cancer research UK news Medical research Health Science Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemoimmunotherapy in Resectable NSCLC Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
Is the use of neoadjuvant immunotherapy combined with chemotherapy a safe and effective therapeutic option for patients with resectable non-small cell lung cancer?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Adjuvant chemotherapy cost effective for operable NSCLC in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Remote 24-Hr Monitoring Improves Life for Patients on Chemo Remote 24-Hr Monitoring Improves Life for Patients on Chemo
Remote 24-hour monitoring of patients with cancer who were receiving chemotherapy helped improve management of side effects and quality of life.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer
The approval is based on phase 3 trial data showing prolonged event-free survival with the pembrolizumab regimen vs neoadjuvant chemotherapy alone for previously untreated stage II or III TNBC.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data showing high antitumor activity in laboratory and mice models. Fidia Farmaceutici, a multinational research company based in Italy, announced the latest FDA designation, which is designed to encourage the development of novel drugs, par...
Source: Asbestos and Mesothelioma News - July 28, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
KENILWORTH, N.J.--(BUSINESS WIRE) July 27, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 27, 2021 Category: Drugs & Pharmacology Source Type: news

A Bristol consultant who completed her PhD while receiving chemotherapy for cancer said the illness was her ‘ tool ’
A paediatric anesthetist finished her PhD at the University of Bristol six months early despite fighting cancer. (Source: University of Bristol news)
Source: University of Bristol news - July 26, 2021 Category: Universities & Medical Training Tags: Student life; Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Mayo Clinic Q & amp;A podcast: Making progress in treating glioblastoma
When it comes to malignant tumors in the brain and spinal cord, glioblastoma is the most common. Glioblastoma is an aggressive form of cancer that forms from cells called astrocytes in the brain or the spinal cord. Glioblastoma can occur at any age, but it's more common in older adults. It can cause worsening headaches, nausea, vomiting and seizures. Glioblastoma can be difficult to treat. Current treatments include surgery, radiation and chemotherapy, but thanks to… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 26, 2021 Category: Databases & Libraries Source Type: news

Chemotherapy can induce mutations that lead to pediatric leukemia relapse
(St. Jude Children's Research Hospital) A collaboration led by St. Jude Children's Research Hospital, Shanghai Children's Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Remote Monitoring System Reduces Chemotherapy Symptom Burden
Significant reductions seen for global distress index, psychological symptoms, physical symptoms of Memorial Symptom Assessment Scale (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 22, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Remote Monitoring System Reduces Chemotherapy Symptom Burden
THURSDAY, July 22, 2021 -- For patients receiving chemotherapy, use of an Advanced Symptom Management System (ASyMS) for real-time remote symptom monitoring reduces symptom burden, according to a study published online July 21 in The BMJ. Roma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 22, 2021 Category: Pharmaceuticals Source Type: news

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Studies find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa
(UNC Lineberger Comprehensive Cancer Center) Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news